Identification of an X-linked locus modifying mouse skin tumor susceptibility

Molecular Carcinogenesis

Volumn 44, Issue 3, 2005, Pages 212-218

  George, Kenneth ^a   Iacobucci, Audrey ^a   Uitto, Jessica ^a   O'Brien, Thomas G ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Ornithine decarboxylase; Transgenic mouse; Tumor modifier loci; X linked modifier

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; DNA; ORNITHINE DECARBOXYLASE; POLYAMINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENETIC LINKAGE; GENOTYPE; MALE; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN TUMOR; TRANSGENE; X CHROMOSOME;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CROSSES, GENETIC; FEMALE; GENE EXPRESSION; GENES, X-LINKED; GENETIC PREDISPOSITION TO DISEASE; LINKAGE (GENETICS); MALE; MICE; SKIN NEOPLASMS; TRANSGENES; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; MUS MUSCULUS;

EID: 27644444681     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20130     Document Type: Article

References (28)

1. O'Brien TG, Megosh LC, Gilliard G, Peralta Soler A. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res 1997;57:2630-2637.
2. Coleman CS, Pegg AE, Megosh L, Guo Y, Sawicki JA, O'Brien TG. Targeted expression of spermidine, spermine N1-acetyltransferase to mouse skin increases susceptibility to chemically-induced skin carcinogenesis. Carcinogenesis 2002;23:359-364.
3. Megosh LC, Hu J, George K, O'Brien TG. Genetic control of polyamine-dependent susceptibility to skin tumorigenesis. Genomics 2002;79:505-512.
4. Nagase H, Bryson S, Cordell H, Kemp CJ, Fee F, Balmain A. Distinct genetic loci control development of benign and malignant skin tumors in mice. Nat Genet 1995;10:424-429.
5. Mock BA, Lowry DT, Rehman I, Padlan C, Yuspa SH, Hennings H. Multigenic control of skin tumor susceptibility in SENCARA/pt mice. Carcinogenesis 1998;19:1109-1115.
6. Angel JM, Beltran L, Minda F, Rupp T, DiGiovanni J. Association of a murine chromosome locus (Ps11) with susceptibility to mouse skin tumor promotion by 12-0-tetradecanolylphorobl-13-acetate. Mol Carcinog 1997;20:162-167.
7. Megosh L, Gilmour SK, Rosson D, et al. Increased skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res 1995;55:4205-4209.
8. Kruglyak L, Lander E. A non parametric approach for mapping quantitative trait loci. Genetics 1995;139:1421-1428.
9. Balding DJ, Bishop M, Cannings C, editors. Handbook of Statistical Genetics. Clichester, England: John Wiley and Sons, Ltd: 2001.
10. Hennings H, Devor D, Wenk ML, et al. Comparison of two-stage epidermal carcinogenesis initiated by 7, 12-dimethylbenz(a)anthracene or N-methyl-N1-nitro-N-nitrosoquanidine in newborn and adult SENCAR and BALB/c mice. Cancer Res 1981;41:773-779.
11. Naito M, DiGiovanni J. Genetic background and development of skin tumors. In: Conti CJ, Slaga TJ, Klein-Szanto AJP, editors. Skin tumors: experimental and clinical aspects. Vol. 3, New York: Raven Press: 1989. p 187-212.
12. Clemens KE, Churchill G, Bhatt N, Richardson K, Noonan FP. Genetic control of susceptibility to UV-induced immunosuppression by interacting quantitative tract loci. Genes Immun 2000;1:251-259.
13. Noonan FP, Muller HK, Fears TR, Kusewitt DF, Johnson TM, DeFabo EC. Mice with genetically determined high susceptibility to ultraviolet (UV)-induced immunosuppression show enhanced UV carcinogenesis. J Invest Dermatol 2003;121:1175-1181.
14. Stong A, Stegmaier C, Jockei KH. Nonmelanoma sin cancer in the Dederal State of Suarland, Germany, 1995-1999. Br J Cancer 2003;89:1205-1208.
15. Boi S, Cristofolini M, Micciolo R, Polla E, DallaPalma P. Epidemiology of skin tumors: Data from the cutaeous cander registry in Trentino, Italy. J Cutan Med Surg 2003;7:300-305.
16. Kahn HS, Tatham LM, Patel AV, Thun MJ, Heath CW. Increased cancer mortality following a history of non-melanoma skin cancer. JAMA 1998;280:910-912.
17. Angele MK, Ayala A, Monfils BA, Cioffi WG, Bland KI, Chaudry IH. Testosterone and/or low estradiol: Normally required but harmful immunologically for males after trauma-hemorrhage. J Trauma 1998;44:78-85.
18. Ashcroft GS, Mills SJ. Androgen receptor-mediated inhibition of cutaneous wound healing. J Clin Invest 2002;110:615-624.
19. Giovannucci E. Is the androgen receptor CAG repeat length significant for prostate cancer? Cancer Epidemiology, Biomarkers & Prevention 2002;11:985.
20. Nelson KA. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 2002;155:883.
21. http://www.ncbi.nlm.nih.gov.
22. http://www.celeradiscoverysystem.com.
23. Janne OA, Crozat A, Palvimo J, Eisenberg LM. Androgen-regulation of ornithine decarboxylase and S-adenosyl-methionine decarboxylase genes. J Steroid Biochem Molec Biol 1991;40:307-315.
24. Betts AM, Waite I, Neal DE, Robson CN. Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display. FEBS Lett 1997;405:328-332.
25. Martinez ME, O'Brien T, Fultz KE, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA 2003;100:7859-7864.
26. Visvanathan K, Helzlsouer K, Boorman D, et al. Association among an ornithine decarboxylase polymorphism, androgen receptor (CAG) repeat length and prostate cancer risk. J Urology 2004;171:652-655.
27. Manenti G, Gariboldi M, Fiorino A, Zedda AI, Pierotti MA, Dragani TA. Genetic mapping of lung cancer modifier loci specifically affecting tumor initiation and progression. Cancer Res 1997;57:4164-4166.
28. Doerge RW, Churchill GA. Permutation tests for multiple loci affecting a quantitative character. Genetics 1996;142:285-294.